Get started
Author

Isabella Nassir

OpenAlex ID: A5042812937
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand‐1 (PD‐L1) expression and increases anti‐tumour effects of T cells in multiple myeloma
2020 · Haiming Chen, Mingjie Li, et al. · British Journal of Haematology · 28
PDF
The JAK1/2 inhibitor ruxolitinib downregulates the immune checkpoint protein B7H3 in multiple myeloma
2022 · Ning Xu, Erin Yu, et al. · Hematological Oncology · 4
Ruxolitinib Enhances Anti-MM Function of Cytotoxic T-Cells By Upregulating IFNγ and Gzmb
2022 · Haiming Chen, Mingjie Li, et al. · Blood · 1
Evaluation of Repotrectinib's Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo
2022 · Haiming Chen, Eric Souther, et al. · Blood · 1
Repotrectinib Alone and in Combination with Immunomodulatory Drugs Exhibits Potent Anti-Multiple Myeloma Activity
2022 · Haiming Chen, Eric Souther, et al. · Blood · 1
The JAK Inhibitor Pacritinib Suppresses the Checkpoint Proteins Pvrig and Tigit Expression on T Cells in Multiple Myeloma Patients
2022 · Ning Xu, Mingjie Li, et al. · Blood
The JAK1/2 Inhibitor Ruxolitinib Downregulates CXCL12 Secretion from Bone Marrow Stromal Cells and M2 Macrophage Polarization in Multiple Myeloma
2019 · Haiming Chen, Mingjie Li, et al. · Blood
The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma
2019 · Ning Xu, Nicole Ng, et al. · Blood
Ruxolitinib Reverses Checkpoint Inhibition By Downregulating PD-L1 and PD-L2 Expression on Both Tumor and Stromal Cells in Multiple Myeloma
2019 · Haiming Chen, Mingjie Li, et al. · Blood
Works count: 9
Citation count: 35
H-index: 2
I10-index: 1
Year
Topic
Type